UTHR Q4 2023 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena

UTHRUnited Therapeutics Corporation

$24B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$615M+25.1% YoY

Gross Profit

$544M88.4% margin

Operating Income

$260M42.3% margin

Net Income

$217M35.3% margin

EPS (Diluted)

$4.36

QoQ Revenue Growth

+0.9%

Cash Flow

Operating Cash Flow

$151M

Free Cash Flow

$72M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$7.2B

Total Liabilities

$1.2B

Stockholders' Equity

$6.0B

Cash & Equivalents

$1.2B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$615M	$492M	+25.1%
Gross Profit	$544M	$436M	+24.8%
Operating Income	$260M	$176M	+48.1%
Net Income	$217M	$132M	+64.3%

Revenue Segments

Tyvaso

$471M64%

Remodulin

$115M16%

Orenitram

$84M11%

Unituxin

$54M7%

Adcirca

$7M1%

Product and Service, Other

$4M1%

Geographic Segments

UNITED STATES

$586M95%

Non-US

$29M5%